secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002874
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel reports prelim Q4 total revenue $57.6M, guides FY2025 rev $200-210M
-------------------------------------------------------------------------

- Q4 2024 total revenue $57.6M vs $35.8M Q4 2023; net product sales $46.5M.
- TAVALISSE net sales $31.0M, REZLIDHIA $7.4M, GAVRETO $8.1M (launched June 2024).
- Full-year 2024 total revenue $179.3M; cash & equivalents $77.3M at year-end.
- 2025 guidance: total revenue $200-210M; expects positive net income for the year.
- R289 granted Orphan Drug designation by FDA for MDS; Phase 1b enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925002874/0001104659-25-002874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925002874/tm253048d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer